Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia

Cheng-Cheng Ma, Ye Chai, Hui ling Chen, Xin Wang, Ying Gao, Wan li Hu and Xue Xiang

Abstract
Blast crisis develops in a minority of patients with chronic myeloid leukemia even in the era of tyrosine kinase inhibitor (TKI) therapy. Reports suggest that we know little about the mechanism of BCR-ABL and AML1-ETO co-expression in blast crisis of chronic myeloid leukemia, and that other chromosomal abnormalities also coexist. Here, we document an unusual and interesting case of a 51-year-old female diagnosed in the chronic phase of chronic myeloid leukemia. After undergoing TKI treatment for 3 months, her bone marrow aspirates in the chronic phase had transformed to blast crisis. Molecular genetic testing indicated she was positive for p210 form of BCR-ABL (copy number decreased from 108.91% to 56.96%) and AML1-ETO fusion (copy number, 5.65%) genes and had additional chromosomal abnormalities of t(8; 21)(q22; q22)/t(9; 22)(q34; q11), t(2; 5)(p24; q13) and an additional +8 chromosome.

Keywords
Clonal evolution, AML1-ETO, BCR-ABL, additional chromosome, blast crisis, chronic myeloid leukemia

Date received: 11 September 2019; accepted: 21 February 2020

Corresponding author:
Ye Chai, Department of Hematology, Lanzhou University Second Hospital, No. 82-Cuiyingmen, Cheng-Guan District, Lanzhou, Gansu 730010, People’s Republic of China.
Email: ery_chaiy@lzu.edu.cn
Introduction

Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL fusion gene on the Philadelphia (Ph) chromosome, which produces the chromosomal translocation t(9; 22). Although the expression of BCR-ABL can be reduced to low or undetectable levels in some patients who respond well to imatinib, blastic transformation is a major challenge following tyrosine kinase inhibitor (TKI) treatment for a minority of CML patients.¹ This suggests a dismal clinical prognosis, while patients in the chronic phase of chronic myeloid leukemia (CML-CP) have little or no response to TKI therapy and progress to blast crisis (BC).² AML1-ETO results from the t(8; 21)(q22; q22) chromosome translocation, which is thought to be associated with a favorable prognosis in acute myeloid leukemia (AML). Nevertheless, additional chromosomal abnormalities (ACAs) and fusion proteins may contribute to accelerating the progression of disease. The BCR-ABL fusion has been reported to interact with class-II mutations because the AML1-ETO[t(8; 21)] fusion is rare in myeloid malignancies.³ However, it is unclear how both BCR-ABL and AML1-ETO positive abnormalities lead to a CML blastic transformation. Clinical research has identified the existence of diverse subclones during the occurrence and progression of AML. If both genes appear in the CML blast crisis, class-I and class-II mutations can promote cell proliferation of myeloid malignancies, leading to a negative prognosis.⁴ Here, we report a rare case of BCR-ABL and AML1-ETO gene co-existence and an additional +8 chromosome in the blastic crisis of CML.

Case report

This study was approved by the Institutional Ethical Committee of Lanzhou University Second Hospital (2019A-329). A 51-year-old female was admitted to our hospital in January 2018 because of an 8-month history of left upper abdominal pain. She was diagnosed with CML and received TKI treatment, but progressed to CML-BC 3 months later. Physical examination after admission showed splenomegaly 3 cm under the ribs. Routine blood analysis showed a white blood cell (WBC) count of $306 \times 10^9/L$, a hemoglobin count of 107 g/L, and a platelet count of $218 \times 10^9/L$, with a classification of 83% neutrophils, 6% lymphocytes, 3% monocytes, 4% basophils, and 4% eosinophils. Basophils were $12.94 \times 10^9/L$ and eosinophils were $12.15 \times 10^9/L$. Biochemistry analysis revealed r-glutamyl transferase 122 U/L and lactate dehydrogenase (LDH) 897 U/L. Regarding bone marrow cell morphology, extremely active proliferation of nucleated cells was evident in the bone marrow and granulocyte proliferation was active; the stage before neutrophilic myelocytes in the bone marrow was dominant, and the number of eosinophilic and basophilic granulocytes had increased compared with normal levels. Karyotype examination on admission (Figure 1) revealed 46, xx, t(9;22)(q34;q11) [20]; the patient was positive for the p210 BCR-ABL gene (gene quantification, 108.91%). Her Sokal score was 0.8. CML-CP was diagnosed and she was treated with imatinib mesylate (400 mg/day).

Around 2 weeks after initiating treatment, routine blood analysis showed a WBC count of $4.7 \times 10^9/L$, a hemoglobin count of 105 g/L, and a platelet count of $275 \times 10^9/L$; splenomegaly had disappeared, suggesting the patient was in a stable condition, and complete hematological remission was achieved. She was readmitted to our hospital in April 2018 because of fatigue and nausea for 8 days and nasal bleeding for 1 day. Routine blood analysis showed a WBC count of
258.43 × 10^9/L, a hemoglobin count of 98 g/L, a platelet count of 24 × 10^9/L, 16% neutrophils, 0% lymphocytes, 0% mononuclear cells, 0.01% basophils, and 0% eosinophils. Her basophilic granulocyte count was 1.63 × 10^9/L and her eosinophil count was 0.21 × 10^9/L. Biochemical analysis revealed γ-glutamyl transferase 318 U/L and LDH 7742 U/L. Regarding bone marrow cell morphology, bone marrow hyperplasia was highly active with 57.5% of primitive cells, relatively fewer lymphocytes, and an increased number of monocytes; CML was considered. Bone marrow biopsy showed a proliferation of granulocytes, erythrocytes, and mesangium, a proliferation of juvenile cells, focal distribution, a small amount of fibrous tissue hyperplasia, and blast crisis of CML. Flow immunotyping showed that the primitive naïve cells accounted for 59.86% of nucleated cells, expressing CD13, CD33, CD34, HLA-DR, myeloperoxidase, and CD38, partially expressing CD117, and weakly expressing CD64. Karyotype analysis was repeated (Figure 2) to show 46, xx, t(9; 22)(q34; q11)[20]. Fifty fusion genes were found, positive quantification of AML1-ETO was 5.65%, and BCR-ABL(P210) positive quantification was 56.96%; thus, CML-BC was considered. On April 16, 2018, the patient suffered a sudden cerebral hemorrhage, family members decided to discontinue treatment, and she died.

**Discussion**

The prognosis of CML is determined by cytogenetic and molecular abnormalities. The AML1-ETO fusion gene results from the t(8; 21)(q22; q22) chromosome translocation, which is considered to be associated with a favorable prognosis in acute myeloid leukemia (AML-M1). However, ACAs and fusion genes may also determine the course
of disease. Moreover, disease progression can occur at any stage through the presence of subclones. Although BCR-ABL is the driving force of disease progression because its reduction is linked to clinical outcomes by TKI treatment, individual BCR-ABL cannot contribute to acute disease.

The latest genetic research shows that one or more mutations is associated with myeloid malignancies, and it is thought that additional mutations besides BCR-ABL can accelerate disease progression. The core binding factor (CBF) of leukemias is t(8; 21)(q22; q22)/AML1-ETO, representing class-II mutations thought to link AML with recurrent genetic abnormalities. These class-II mutations are assumed to cooperate with other mutation types that promote cell proliferation (‘class-I mutations’), such as those in FLT3, RAS, KIT, and JAK2 genes. According to these two hypotheses, most acute leukemias are the consequence of a collaboration of several types of mutations, which is similar to the pathogenesis of the blast crisis of CML. The BCR-ABL mutation is a common class-I mutation which promotes abnormal cell proliferation. Nevertheless, the downregulation of BCR-ABL gene expression together with AML1-ETO gene positivity is rare in CML-BC, and the poor prognosis of this disease suggests it is caused by a mutation in BCR-ABL. Hence, the BCR-ABL gene quantification decreased in our patient but CML-CP progressed to BC, which was not consistent with the pathogenesis of CML-BC following effective TKI treatment.

In CML-BC, a newly acquired structural transformation other than a BCR-ABL translocation, including mutations, structural variants, and copy number abnormalities, occurs in the majority of cases of BC. Additionally, more than one cytogenetic
abnormality may be involved. Only after the quantitative downregulation of the BCR-ABL gene in the present patient did CML-CP evolve to CML-BC with the appearance of AML1-ETO gene positivity, and little is known about existing clone evolution. The clonal evolution mechanism of the CML mutation may be related to the dominant cloning caused by the proliferation of subclones. Current molecular biology research suggests that tumor evolution in disease progression may be caused by mutations in tumor clone-specific genes, with changes documented in tumor genes, chromosomes, and immunophenotypes; however, tumor clones still persist.

Five cases of secondary AML, except CML-BC, have previously been reported, suggesting that Ph+ is a secondary aberration. Similarly, the quantitative downregulation of the BCR-ABL gene along with AML1-ETO positivity in existing CML-BC subclones is rare. This was reported in our CML-CP patient initially in a median risk cytogenetics group, who eventually died. It is unclear whether these subclones were apparent at the initial diagnosis or appeared during disease progression. In the case of our patient, we believe that the existing subclone appeared during the change from CML-CP to CML-BC, similar to other secondary AMLs. This is because she had a good response to earlier TKI treatment, as seen by the downregulation of over 50% of BCR-ABL gene expression. Conversely, in rare cases of CML appearing as de novo BC or rapidly progressing to advanced phases, the Ph translocation was concurrently seen with an inv(16)/CBFB-MYH11.9

Recently, Singh et al.10 suggested that analysis of copy number variations, expression profiling, and genome-wide scoring of single nucleotide polymorphisms in different phases of imatinib-treated CML will help our understanding of the resistance mechanism to TKIs. Early use of TKIs was reported to significantly reduce the copy number of BCR-ABL and inhibit the primary clone, while the gradual emergence of subclones was seen with increasing TKI resistance.11 It is conceivable that TKI resistance is related to subcloning.

In a retrospective study of 2,326 CML patients, Gong et al.12,13 reported that +8 is a major route for ACA, suggesting a good prognosis in the early stages of disease or during therapy. The effect of the prognosis of ACAs will only be reduced if the disease progresses to BC, regardless of the category or complexity of ACAs. Furthermore, the impact of ACA prognosis is related to disease type and stage, and ACAs play an important role in accelerating BC.13–15 However, little is known about how each ACA promotes to BC in the TKI era.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD
Cheng-Cheng Ma https://orcid.org/0000-0002-4807-0222

References
1. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.
2. Ochi Y, Yoshida K, Huang Y, et al. Molecular profiling of blastic transformation in chronic myeloid leukemia. Blood 2018; 132: 1725.
3. Bacher U, Haferlach T, Alpermann T, et al. Subclones with the t(9; 22)/BCR-ABL1 rearrangement occur in AML and seem to
cooperate with distinct genetic alterations. *Br J Haematol* 2011; 152: 713–720.

4. Singh MK, Gupta R, Rahman K, et al. Co-existence of AML1-ETO and BCR-ABL1 transcripts in a relapsed patient of acute myeloid leukemia with favorable risk group: A coincidence or clonal evolution. *Hematol Oncol Stem Cell Ther* 2017; 10: 39–41.

5. Hehlmann R. How I treat CML blast crisis. *Blood* 2012; 120: 737–747.

6. de Guzman CG, Warren AJ, Zhang Z, et al. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. *Mol Cell Biol* 2002; 22: 5506–5517.

7. Zhou T, Medeiros LJ and Hu S. Chronic myeloid leukemia: beyond BCR-ABL1. *Curr Hematol Malig Rep* 2018; 13: 435–445.

8. Preuner S, Mitterbauer G, Mannhalter C, et al. Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia. *Eur J Cancer* 2012; 48: 233–236.

9. Merzianu M, Medeiros LJ, Cortes J, et al. inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases. *Am J Clin Pathol* 2005; 124: 807–814.

10. Singh N, Tripathi AK, Sahu DK, et al. Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia. *Oncotarget* 2018; 9: 30385–30418.

11. Marktel S, Martin D, Foot N, et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. *Hematologika* 2002; 3: 260–267.

12. Wang W, Cortes JE, Lin P, et al. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. *Leukemia* 2015; 29: 2263–2266.

13. Gong Z, Medeiros LJ, Cortes JE, et al. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. *Blood Adv* 2017; 1: 2541–2552.

14. Chen Z, Shao C, Wang W, et al. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. *Leukemia* 2017; 31: 585–592.

15. Chen Z, Wang W, Cortes JE, et al. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. *Blood Cancer J* 2016; 6: e418.